Cargando…
A community-partnered approach for diversity in COVID-19 vaccine clinical trials
INTRODUCTION: Communities of color have faced disproportionate morbidity and mortality from COVID-19, coupled with historical underrepresentation in US clinical trials, creating challenges for equitable participation in developing and testing a safe and effective COVID-19 vaccine. METHODS: To increa...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874035/ https://www.ncbi.nlm.nih.gov/pubmed/36714798 http://dx.doi.org/10.1017/cts.2022.471 |
_version_ | 1784877714035965952 |
---|---|
author | Castellon-Lopez, Yelba Landovitz, Raphael Ntekume, Ejiro Porter, Courtney Bross, Rachelle Hilder, Robin Lucas-Wright, Aziza Daar, Eric S. Chavez, Pedro Blades, Christopher Carson, Savanna Morris, D’Ann Vassar, Stefanie Casillas, Alejandra Brown, Arleen |
author_facet | Castellon-Lopez, Yelba Landovitz, Raphael Ntekume, Ejiro Porter, Courtney Bross, Rachelle Hilder, Robin Lucas-Wright, Aziza Daar, Eric S. Chavez, Pedro Blades, Christopher Carson, Savanna Morris, D’Ann Vassar, Stefanie Casillas, Alejandra Brown, Arleen |
author_sort | Castellon-Lopez, Yelba |
collection | PubMed |
description | INTRODUCTION: Communities of color have faced disproportionate morbidity and mortality from COVID-19, coupled with historical underrepresentation in US clinical trials, creating challenges for equitable participation in developing and testing a safe and effective COVID-19 vaccine. METHODS: To increase diversity, including racial and ethnic representation, in local Los Angeles County NIH-sponsored Phase 3 SARS-CoV-2 vaccine clinical trials, we used deliberative community engagement approaches to form a Community Consultant Panel (CCP) that partnered with trial research teams. Thirteen members were recruited, including expertise from essential workers, community-based and faith-based organizations, or leaders from racial and ethnic minority communities. RESULTS: Working closely with local investigators for the vaccine studies, the CCP provided critical insight on best practices for community trust building, clinical trial participation, and reliable information dissemination regarding COVID-19 vaccines. Modifying recruitment, outreach, and trial protocols led to majority–minority participants (55%–78%) in each of the three vaccine clinical trials. CCP’s input led to cultural tailoring of recruitment materials, changes in recruitment messaging, and supportive services to improve trial accessibility and acceptability (transportation, protocols for cultural competency, and support linkages to care in case of an adverse event). Barriers to clinical trial participation unable to be resolved included childcare, requests for after-hours appointment availability, and mobile locations for trial visits. CONCLUSION: Using deliberative community engagement can provide critical and timely insight into the community-centered barriers to COVID-19 vaccine trial participation, including addressing social determinants of health, trust, clinical trial literacy, structural barriers, and identifying trusted messenger and reliable sources of information. |
format | Online Article Text |
id | pubmed-9874035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98740352023-01-25 A community-partnered approach for diversity in COVID-19 vaccine clinical trials Castellon-Lopez, Yelba Landovitz, Raphael Ntekume, Ejiro Porter, Courtney Bross, Rachelle Hilder, Robin Lucas-Wright, Aziza Daar, Eric S. Chavez, Pedro Blades, Christopher Carson, Savanna Morris, D’Ann Vassar, Stefanie Casillas, Alejandra Brown, Arleen J Clin Transl Sci Research Article INTRODUCTION: Communities of color have faced disproportionate morbidity and mortality from COVID-19, coupled with historical underrepresentation in US clinical trials, creating challenges for equitable participation in developing and testing a safe and effective COVID-19 vaccine. METHODS: To increase diversity, including racial and ethnic representation, in local Los Angeles County NIH-sponsored Phase 3 SARS-CoV-2 vaccine clinical trials, we used deliberative community engagement approaches to form a Community Consultant Panel (CCP) that partnered with trial research teams. Thirteen members were recruited, including expertise from essential workers, community-based and faith-based organizations, or leaders from racial and ethnic minority communities. RESULTS: Working closely with local investigators for the vaccine studies, the CCP provided critical insight on best practices for community trust building, clinical trial participation, and reliable information dissemination regarding COVID-19 vaccines. Modifying recruitment, outreach, and trial protocols led to majority–minority participants (55%–78%) in each of the three vaccine clinical trials. CCP’s input led to cultural tailoring of recruitment materials, changes in recruitment messaging, and supportive services to improve trial accessibility and acceptability (transportation, protocols for cultural competency, and support linkages to care in case of an adverse event). Barriers to clinical trial participation unable to be resolved included childcare, requests for after-hours appointment availability, and mobile locations for trial visits. CONCLUSION: Using deliberative community engagement can provide critical and timely insight into the community-centered barriers to COVID-19 vaccine trial participation, including addressing social determinants of health, trust, clinical trial literacy, structural barriers, and identifying trusted messenger and reliable sources of information. Cambridge University Press 2022-10-06 /pmc/articles/PMC9874035/ /pubmed/36714798 http://dx.doi.org/10.1017/cts.2022.471 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. |
spellingShingle | Research Article Castellon-Lopez, Yelba Landovitz, Raphael Ntekume, Ejiro Porter, Courtney Bross, Rachelle Hilder, Robin Lucas-Wright, Aziza Daar, Eric S. Chavez, Pedro Blades, Christopher Carson, Savanna Morris, D’Ann Vassar, Stefanie Casillas, Alejandra Brown, Arleen A community-partnered approach for diversity in COVID-19 vaccine clinical trials |
title | A community-partnered approach for diversity in COVID-19 vaccine clinical trials |
title_full | A community-partnered approach for diversity in COVID-19 vaccine clinical trials |
title_fullStr | A community-partnered approach for diversity in COVID-19 vaccine clinical trials |
title_full_unstemmed | A community-partnered approach for diversity in COVID-19 vaccine clinical trials |
title_short | A community-partnered approach for diversity in COVID-19 vaccine clinical trials |
title_sort | community-partnered approach for diversity in covid-19 vaccine clinical trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874035/ https://www.ncbi.nlm.nih.gov/pubmed/36714798 http://dx.doi.org/10.1017/cts.2022.471 |
work_keys_str_mv | AT castellonlopezyelba acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT landovitzraphael acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT ntekumeejiro acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT portercourtney acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT brossrachelle acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT hilderrobin acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT lucaswrightaziza acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT daarerics acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT chavezpedro acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT bladeschristopher acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT carsonsavanna acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT morrisdann acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT vassarstefanie acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT casillasalejandra acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT brownarleen acommunitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT castellonlopezyelba communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT landovitzraphael communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT ntekumeejiro communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT portercourtney communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT brossrachelle communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT hilderrobin communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT lucaswrightaziza communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT daarerics communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT chavezpedro communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT bladeschristopher communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT carsonsavanna communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT morrisdann communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT vassarstefanie communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT casillasalejandra communitypartneredapproachfordiversityincovid19vaccineclinicaltrials AT brownarleen communitypartneredapproachfordiversityincovid19vaccineclinicaltrials |